A review of the scientific basis for uncertainty factors for use in quantitative risk assessment for the induction of allergic contact dermatitis

Contact Dermatitis

Volumn 47, Issue 5, 2002, Pages 257-266

  Felter, Susan P ^a   Robinson, Michael K ^a   Basketter, David A ^b   Frank Gerberick, G ^a  

^a PROCTER AND GAMBLE COMPANY   (United States)

^b UNILEVER RESEARCH   (United Kingdom)

Author keywords

Allergic contact dermatitis; Data extrapolation; Sensitization risk assessment; Sensitization uncertainty factors; Skin

Indexed keywords

ALLERGEN; IRRITANT AGENT; PENETRATION ENHANCING AGENT;

ANIMAL EXPERIMENT; DATA ANALYSIS; ENVIRONMENTAL FACTOR; OCCLUSION; QUANTITATIVE ANALYSIS; REVIEW; RISK ASSESSMENT; SKIN ALLERGY; SKIN SENSITIZATION; TOXICITY;

DATA INTERPRETATION, STATISTICAL; DERMATITIS, ALLERGIC CONTACT; EVIDENCE-BASED MEDICINE; HUMANS; NO-OBSERVED-ADVERSE-EFFECT LEVEL; RISK ASSESSMENT; UNCERTAINTY;

EID: 0036877375     PISSN: 01051873     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0536.2002.470502.x     Document Type: Review

References (61)

1. Lehman A L, Fitzhugh O G. 100-fold margin of safety. Q Bull Assoc Food Drug Off US 1954: 18: 33-35.
2. WHO (World Health Organization). Procedures for the testing of intentional food additives to establish their safety for use. Second Report of the Joint FAO/WHO Expert Committee on Food Additives. Technical Report Series, no. 144. Geneva: WHO, 1958.
3. Dourson M L, Stara J F. Regulatory history and experimental support of uncertainity (safety) factors. Reg Toxicol Pharmacol 1983: 3: 224-228.
4. Burin G J, Saunders D R. Addressing human variability in risk assessment. The robustness of the intraspecies uncertainty factor. Reg Tox Pharmacol 1999: 30: 209-216.
5. Renwick A G, Lazarus N R. Human variability and noncancer risk assessment - An analysis of the default uncertainty factor. Reg Tox Pharmacol 1998: 27: 3-20.
6. Chappell W R, Mordenti J. Extrapolation of toxicological and pharmacological data from animals to humans. Adv Drug Res 1991: 20: 1-116.
7. Travis C C, White R K. Interspecific scaling of toxicity data. Risk Anal 1988: 8: 116-125.
8. Kramer H J, van den Ham W A, Slob W, Pieters M N. Conversion factors estimating indicative chronic no-observed-adverse-effect levels from short-term toxicity data. Reg Tox Pharmacol 1996: 23: 249-255.
9. Nessel C S, Lewis S C, Stauber K L, Adgate J L. Subchronic to chronic exposure extrapolation: Toxicologic evidence for a reduced uncertainty factor. Human Ecol Risk Assess 1995: 1: 516-526.
10. Pieters M N, Kramer H J, Slob W. Evaluation of the uncertainty factor for subchronic-to-chronic extrapolation: Statistical analysis of toxicity data. Reg Tox Pharmacol 1998: 27: 108-111.
11. Dourson M L, Felter S P, Robinson D. Evolution of science-based uncertainty factors for non-cancer risk assessment. Reg Toxicol Pharmacol 1996: 24: 108-120.
12. USEPA (US Environmental Protection Agency). Reference dose (RfD). Description and use in health risk assessments. http:http://www.epa.gov/iris/rfd.htm, 1993.
13. ECETOC (European Centre for Ecotoxicology and Toxicology of Chemials). Assessment factors in human health risk assessment. ECETOC Technical Report no. 68. Brussels: ECETOC, 1995.
14. WHO/IPCS (World Health Organization/International Programme for Chemical Safety). Assessing human health risks of chemicals: derivation of guidance values for health-based exposure limits. Environmental Health Criteria 170. Geneva: WHO/IPCS, 1994.
15. Gerberick G F, Robinson M K. A skin sensitization risk assessment approach for evaluation of new ingredients and products. Am J Contact Dermatits 2000: 11: 65-73.
16. Gerberick G F, Robinson M K, Felter S P, White I R, Basketter D A. Understanding fragrance allergy using an exposure-based risk assessment approach. Contact Dermatitis 2001: 45: 333-340.
17. ICCVAM (Interagency Coordinating Committee on the Validation of Alternative Methods). The murine local lymph node assay: a test method for assessing the allergic contact dermatitis potential of chemicals/compounds. NIH publication no. 99-4494, 1999.
18. Basketter D A, Blaikie L, Dearman R J et al. Use of the local lymph node assay for the estimation of relative contact allergenic potential. Contact Dermatitis 2000: 42: 344-348.
19. Robinson M K. Population differences in skin structure and physiology and the susceptibility to irritant and allergic contact dermatitis: implications for skin safety testing and risk assessment. Contact Dermatits 1999: 41: 65-79.
20. Cassimos C, Kanakoudi-Tsakalidis F, Spyroglou K, Ladianos M, Tzaphi R. Skin sensitization to 2,4-dinitrochloro-benzene (DNCB) in the first months of life. J Clin Lab Immunol 1980: 3: 111-113.
21. Epstein W L. Contact-type delayed hypersensitivity in infants and children: induction of Rhus sensitivity. Pediatrics 1961: 27: 51-53.
22. Lejman E, Stoudemayer T, Grove G, Kligman A M. Age differences in poison ivy dermatitis. Contact Dermatitis 1984: 11: 163-167.
23. Leyden J L, Kligman A M. Allergic contact dermatitis: sex differences. Contact Dermatitis 1977: 3: 333-336.
24. Jordan W P Jr, King S E. Delayed hypersensitivity in females. The development of allergic contact dermatitis in females during the comparison of two predictive patch tests. Contact Dermatitis 1977: 3: 19-26.
25. Rees J L, Friedmann P S, Matthews J N. Sex differences in susceptibility to development of contact hypersensitivity to dinitrochlorobenzene (DNCB). Br J Dermatol 1989: 120: 371-374.
26. Epstein W L. Induction of allergic contact dermatitis in patients with the lymphoma-leukemia complex. J Invest Derm 1958: 30: 30-53.
27. Rostenberg A, Kanof N M. Studies in eczematous sensitizations: I. A comparison between the sensitizing capacities of two allergens and between two different strengths of the same allergen and the effect of repeating the sensitizing dose. J Invest Derm 1941: 4: 505-516.
28. Kligman A M. The identification of contact allergens by human assay. II. Factors influencing the induction and measurement of allergic contact dermatitis. J Invest Derm 1966: 47: 375-392.
29. Lidén S, Beckman L, Cedergren B, Goransson K, Nyquist H. HLA antigens in allergic contact dermatitis. Acta Derm Venereol 1978: 58 (Suppl): 53-56.
30. Karvonen J, Silvennoinen-Kassinen S, Ilonen J, Jakkula H, Tiilikainen A. HLA antigens in nickel allergy. Ann Clin Res 1984: 16: 211-212.
31. Mozzanica N, Rizzolo L, Veneroni G, Diotti R, Hepeisen S, Finzi A F. HLA-A, B, C, and DR antigens in nickel contact sensitivity. Br J Dermatol 1990: 122: 309-313.
32. Smith C K, Hotchkiss S A M, eds. Allergic Contact Dermatitis: Chemical and Metabolic Mechanisms. London: Taylor & Francis, 2001.
33. Dupuis G. Studies on poison ivy. In vitro lymphocyte transformation by urushiol-protein conjugates. Br J Dermatol 1979: 101: 617-624.
34. Friedmann P S, Moss C. Quantification of contact hypersensitivity in man. In: Maibach H I, Lowe N J, eds. Models in Dermatology, Vol. 2. Basel: Karger, 1985: 275-281.
35. White S I, Friedmann P S, Moss C. The effect of altering area of application and dose per unit area on sensitization by DNCB. Br J Dermatol 1986a: 115: 663-668.
36. Moss C, Friedmann P S, Shuster S, Simpson J M. Susceptibility and amplification of sensitivity in contact dermatitis. Clin Exp Immunol 1985: 61: 232-241.
37. Friedmann P S. The immunology of allergic contact dermatitis: The DNCB story. Adv Dermatol 1990: 5: 175-196.
38. White S I, Friedmann P S, Stratton A. HLA antigens and Langerhans' cell density in contact dermatitis. Br J Dermatol 1986: 115: 447-452.
39. Scheuplein R, Ross L. Effects of surfactants and solvents on the permeability of epidermis. J Soc Cosmet Chem 1970: 21: 853-873.
40. Dearman R J, Cumberbatch M, Hilton J et al. Influence of dibutyl phthalate on dermal sensitization to fluorescein isothiocyanate. Fund Appl Toxicol 1996: 33: 24-30.
41. Smith H R, Holloway D, Armstrong D K B, Basketter D A, McFadden J P. Irritant thresholds in subjects with colophony allergy. Contact Dermatits 2000: 42: 95-97.
42. Heylings J R, Clowes H M, Cumberbatch M et al. Sensitization to 2,4-dinitrochlorobenzene. Influence of vehicle on absorption and lymph node activation. Toxicology 1996: 109: 57-65.
43. Cumberbatch M, Scott R C, Basketter D A et al. Influence of sodium lauryl sulphate on 2,4-dinitrochlorobenzene-induced lymph node activation. Toxicology: 1993: 77: 181-191.
44. Robinson M K, Parsell K W, Breneman D L, Cruze C A. Evaluation of the primary skin irritation and allergic contact sensitization potential of transderman triprolidine. Fund Appl Toxicol 1991: 17: 103-119.
45. Barry B W. Dermatological Formulations: Percutaneous Absorption. New York: Marcel Dekker, 1983.
46. Wiechers J. Excipients in topical drug formulations. Manufacturing Chem 1998: July: 17-21.
47. Southwell D, Barry B W. Penetration enhancers for human skin. Mode of action of 2-pyrrolidone and dimethylformamide on partition and diffusion of model compounds water, n-alcohols, and caffeine. J Invest Dermatol 1983: 80: 507-514.
48. Marzulli F N, Maibach H I. Effects of vehicles and elicitation concentration in contact dermatitis testing: I. Experimental contact sensitization in humans. Contact Dermatitis 1976: 2: 325-329.
49. Basketter D A, Gerberick G F, Kimber I. Skin sensitization, vehicle effects and the local lymph node assay. Food Chem Toxicol 2001: 39: 621-627.
50. Lea L J, Warbrick V, Dearman R J, Harvey P, Kimber I, Basketter D A. The impact of vehicle on assessment of relative skin sensitization potency of the 1,4-dihydroquinone in the local lymph node assay. Am J Contact Dermatitis 1999: 10: 213-218.
51. Warbrick E V, Dearman R J, Basketter D A, Kimber I. Influence of application vehicle on skin sensitization to methylchloroisothiazolinone/methylisothiazolinone: an analysis using the local lymph node assay. Contact Dermatitis 1999: 41: 325-329.
52. Robinson M K, Cruze C A. Preclinical skin sensitization testing of antihistamines: Guinea pig and local lymph node assay responses. Food Chem Toxicol 1996: 34: 495-506.
53. Feldmann R J, Maibach H I. Absorption of some organic compounds through the skin in man. J Invest Derm 1969: 54: 339-404.
54. Kalish R, Wood J A, Wille J J, Kydonieus A. Sensitization of mice to topically applied drugs: albuterol, chlorpheniramine, clonidine and nadolol. Contact Dermatitis 1996: 35: 76-82.
55. Garb J. Nevus verrucosus unilateralis cured with podophyllin ointment. Arch Dermatol 1960: 81: 606-609.
56. Bucks D A W, Maibach H I, Guy R H. Occlusion does not uniformly enhance penetration in vivo. In: Bronaugh R L, Maibach H I, eds. Percutaneous Absorption: Mechanisms - Methodology - Drug Delivery. New York: Marcel Dekker, 1989: 77-93.
57. Benfeldt E, Serup J, Menné T. Effect of barrier perturbation on cutaneous salicylic acid penetration in human skin: in vivo pharmacokinetics using microdialysis and noninvasive quantification of barrier function. Br J Dermatol 1999: 140: 739-748.
58. Edman B. The influence of shaving method on perfume allergy. Contact Dermatits 1994: 31: 291-292.
59. Hosoi J, Hariya T, Denda M, Tsuchiya T. Regulation of the cutaneous allergic reaction by humidity. Contact Dermatitis 2000: 42: 81-84.
60. Basketter D A, Griffiths H A, Wang X M, Wilhelm K P, McFadden J. Individual, ethnic and seasonal variability in irritant susceptibility of skin: the implications for a predictive human patch test. Contact Dermatitis 1996: 35: 208-213.
61. Uter W, Geier J, Land M, Pfahlberg A, Gefeller O, Schnuch A. Another look at seasonal varaiation in patch test results. A multifactorial analysis of surveillance data of the IVDK (Information Network of Departments of Dermatology; University of Göttingen, Germany). Contact Dermatitis 2001: 44: 146-152.